RNAC at a glance
Cartesian Therapeutics, Inc. (RNAC, SEC CIK 1453687) filed its latest 10-K annual report on March 9, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and Form 4 insider filings as recently as April 6, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Cartesian Therapeutics, Inc. (RNAC) reported revenue of $400,000 (down 99.0% from FY2024) and a net loss of $130.3 million. Diluted EPS was -$5.02.
- As of September 30, 2026, 21 institutional investment managers tracked by SignalX reported holding Cartesian Therapeutics, Inc. (RNAC) shares worth $21.9 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Miljkovic Milos on January 6, 2026 of 3,573 shares at $6.82 per share.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $400K
- −99.0% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 21 funds
- $21.9M · +0 vs prior quarter
- Latest 8-K
- Nov 5, 2026
- Item 2.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business: Late clinical-stage biopharma pioneering outpatient mRNA-engineered autologous cell therapies for autoimmune diseases targeting B-cell maturation antigen (BCMA)
- New emphasis: Expansion of Descartes-08 into myositis (dermatomyositis, antisynthetase syndrome) with FDA IND accepted December 2025, Phase 2 trial to start H1 2026
- Strategic shift: Prioritization of Descartes-08 development after pausing Descartes-08 in SLE and halting Descartes-15 for multiple myeloma to focus on MG and myositis
- Quantitative highlight: Over 100 patients treated with Descartes-08 outpatient through Phase 1/2 trials; Phase 3 AURORA trial launched May 2025 targeting 100 MG patients
- Noteworthy: FDA granted Orphan Drug, RMAT, and Rare Pediatric Disease Designations for Descartes-08; first mRNA CAR-T with no CRS, neurotoxicity, or genomic integration risks reported
Risk Factors
- FDA investigation of T-cell malignancy risk for CAR-T therapies including Descartes-08, with potential for boxed warnings or REMS requirements in 2024-2025
- Geopolitical conflict risks delaying patient enrollment in clinical trials, impacting multinational trial sites and timelines
- Supply chain vulnerability due to reliance on third-party manufacturers for patient-specific mRNA CAR-T product candidates
- Competition from DNA-based CAR-T therapies with established FDA approvals and safety track records
- Cash burn risks from clinical trial delays and increased development costs, with potential premature trial termination impacting financial condition
Management Discussion & Analysis
- Revenue $2.8M in 2025 vs $38.9M in 2024, collaboration and license revenue down $37.9M primarily from Sobi License milestone
- Operating expenses $146.2M in 2025 vs $82.8M in 2024, R&D up 29% to $58.0M, G&A slightly up 4% to $31.5M
- Operating loss $(143.4)M in 2025 vs $(43.9)M in 2024; net loss $(130.3)M vs $(77.4)M, loss increased 68%
- Best segment: Grant revenue $2.4M in 2025, up $1.8M; worst segment: collaboration/license revenue down 99% to $0.4M
- Cash $126.9M at year-end; $60.25M raised via Series A Preferred in 2023 Private Placement; no product sales yet
- Management expects continued significant R&D, operating losses, and reliance on equity/debt financings; revenue from product sales not expected for several years
AI summary of the RNAC 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- New dilution risk: equity issuance or Loan Agreement conversions could reduce ownership and depress common-stock price
- New debt-covenant risk: May 2026 K2HV Loan Agreement secured substantially all assets, excluding intellectual property
- Liquidity risk: minimum unrestricted cash requirement equals 80% of lender obligations beginning April 1, 2027
- Commercial risk: $40.0 million trailing three-month net product revenue covenant begins January 1, 2029
- Default risk: K2HV may accelerate obligations after an event of default, potentially exceeding available cash
Management Discussion & Analysis
- Quarterly revenue $0 vs $0.5M, down 100% YoY, reflecting no grant revenue
- Net loss $11.5M vs $35.9M, operating loss $25.0M vs $21.1M YoY
- R&D $15.6M, up $1.8M, led by Descartes-08 MG at $6.5M vs $5.4M
- Cash, equivalents and restricted cash $124.7M, operating cash use $70.9M for nine months
- Financing provided $69.6M, including $46.0M term-loan proceeds and $22.8M ATM proceeds
- Outlook: continued losses and higher R&D spending, funding runway at least 12 months, additional financing required
AI summary of the RNAC 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q3 2026 financial results announced for quarter ended September 30, 2026
- Full results and management commentary available in Exhibit 99.1
Item EX-99.1: Item EX-99.1
- Q3 net loss $11.5M, or $0.38 per share, versus $35.9M, or $1.38, in Q3 2025
- Cash $124.7M, including $50M K2HV financing, expected to fund operations into 2028
Item 8.01: Other Events
- Five MG patients retreated after symptom recurrence at median 16.6 months following initial Descartes-08 treatment
- Month 12 post-retreatment outcomes: MG-ADL reduction 6.6 points and MGC reduction 15 points from baseline
Item 7.01: Regulation FD Disclosure
- Phase 2 Descartes-08 retreatment data update in myasthenia gravis
- Additional clinical data may influence confidence in durability and retreatment strategy
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 results announced for quarter ended June 30, 2026
- Full financial results and management commentary available in Exhibit 99.1
Item EX-99.1: Item EX-99.1
- Phase 3 AURORA MG data expected 1Q27, with BLA filing planned for mid-2027; primary value inflection for Descartes-08
- Cash, equivalents and restricted cash $149.3M, supporting planned operations into 2028 alongside four expected clinical readouts
AI summaries of RNAC 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for RNAC
Don't miss the next RNAC filing
- Alerts as it files. A push when RNAC files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut RNAC, by share count.
- Ask anything. An AI agent that reads every RNAC filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Hoge Elizabeth | M | Apr 2, 2026 | 758,001 | - |
| Hoge Elizabeth | M | Apr 2, 2026 | 22,740.03 | - |
| Kalayoglu Murat | M | Apr 2, 2026 | 22,740.03 | - |
| Kalayoglu Murat | M | Apr 2, 2026 | 758,001 | - |
| Singer Michael | G | Mar 13, 2026 | 6,555 | - |
| Miljkovic Milos | Sell | Jan 6, 2026 | 3,573 | $6.82 |
| Brunn Carsten | Sell | Jan 6, 2026 | 23,766 | $6.82 |
| Davis Blaine | Sell | Jan 6, 2026 | 10,591 | $6.82 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $38.3M | $400K |
| Operating Income | - | -$43.9M | -$143.4M |
| Net Income | -$219.7M | -$77.4M | -$130.3M |
| Op. Margin | - | -114.7% | -35851.3% |
| Net Margin | - | -202.3% | -32575.5% |
| Balance Sheet | |||
| Total Assets | $305.1M | $435.0M | $296.4M |
| Equity | - | -$6.8M | -$126.2M |
| ROE | - | 1138.3% | 103.2% |
| Per Share | |||
| EPS | $-1.66 | $-4.49 | $-5.02 |
| Cash Flow | |||
| Operating CF | - | -$23.7M | -$73.9M |
| CapEx | $206K | $9.1M | $5.5M |
Source: XBRL data in Cartesian Therapeutics, Inc. (RNAC)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate RNAC share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 21 | $21.9M |
| Q2 2026 | 21 | $36.0M |
| Q1 2026 | 19 | $18.2M |
| Q4 2025 | 17 | $24.4M |
| Q3 2025 | 13 | $38.9M |
| Q2 2025 | 13 | $41.5M |
| Q1 2025 | 13 | $46.9M |
| Q4 2024 | 10 | $62.5M |
- Two Sigma Investments+71.1K (+24%)
- Renaissance Technologies LLC+51.9K (+256%)
- State Street Corp+12.5K (+5%)
- Morgan Stanley+6.5K (+67%)
- Vanguard Portfolio Management LLC+1.6K (+2%)
- Millennium Management−88.0K (-28%)
- AQR Capital Management−69.3K (-19%)
- Bank of America Corp−49.4K (-58%)
- Goldman Sachs Group−29.0K (-36%)
- BlackRock−10.8K (-1%)
- Citadel Advisors LLC+70.0K
- FMR LLC (Fidelity)−368.4K
Source: 13F-HR filings on SEC EDGAR (aggregated from 127 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
RNAC filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 10-Q | Nov 5, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 5, 2026 | - | Analysis | - |
| 8-K | Sep 29, 2026 | - | Analysis | - |
| SC 13G | Aug 13, 2026 | - | - | |
| 10-Q | Aug 6, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 8-K | Jun 17, 2026 | - | Analysis | - |
| 8-K | Jun 9, 2026 | - | Analysis | |
| 8-K | May 26, 2026 | - | Analysis | |
| 8-K | Apr 30, 2026 | - | Analysis | - |
| 10-Q | Apr 30, 2026 | Mar 31, 2026 | Analysis | |
| 4 | Apr 6, 2026 | - | - | - |
| 4 | Apr 6, 2026 | - | - | - |
| 8-K | Mar 30, 2026 | - | - | - |
| 4 | Mar 13, 2026 | - | - | - |
| SC 13G | Mar 13, 2026 | - | - | |
| 10-K | Mar 9, 2026 | Dec 31, 2025 | Analysis | |
| 8-K | Mar 9, 2026 | - | Analysis | - |
| 8-K | Jan 9, 2026 | - | - | |
| 4 | Jan 8, 2026 | - | - | |
| 4 | Jan 8, 2026 | - | - | |
| 4 | Jan 8, 2026 | - | - | |
| 4 | Jan 6, 2026 | - | - | |
| 4 | Jan 6, 2026 | - | - | |
| 4 | Jan 6, 2026 | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
RNAC SEC filings: frequently asked questions
Which institutions hold RNAC stock?
As of September 30, 2026, the largest Cartesian Therapeutics, Inc. (RNAC) holders among the 13F filers tracked by SignalX were BlackRock ($5.8 million), Vanguard Capital Management LLC ($4.0 million), Two Sigma Investments ($2.6 million), AQR Capital Management ($2.1 million), State Street Corp ($1.9 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was RNAC's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Cartesian Therapeutics, Inc. (RNAC) reported revenue of $400,000 (down 99.0% from FY2024) and a net loss of $130.3 million. Diluted EPS was -$5.02. The figures come from the XBRL data in the 10-K.
What are the main risks in RNAC's latest 10-K?
In the 10-K filed March 9, 2026, Cartesian Therapeutics, Inc. (RNAC) flagged: FDA investigation of T-cell malignancy risk for CAR-T therapies including Descartes-08, with potential for boxed warnings or REMS requirements in 2024-2025. Geopolitical conflict risks delaying patient enrollment in clinical trials, impacting multinational trial sites and timelines. (AI summary of the Risk Factors section.)
What did RNAC report in its latest 8-K?
Cartesian Therapeutics, Inc. (RNAC) filed an 8-K on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 financial results announced for quarter ended September 30, 2026.
What are the latest RNAC SEC filings?
Cartesian Therapeutics, Inc. (RNAC) filed its latest 10-K annual report on March 9, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and a Form 4 insider filing on April 6, 2026.
What is RNAC's SEC CIK number?
Cartesian Therapeutics, Inc. (RNAC)'s SEC Central Index Key (CIK) is 1453687. EDGAR lists every RNAC filing under that number.
Ask anything about RNAC
The research agent reads RNAC's filings, financials, insider trades and 13F holders, then answers with sources.